On September 26, 2024 Epitopea, a transatlantic cancer immunotherapy company, and CQDM reported the launch of a collaborative research project between Epitopea and Université de Montréal (UdeM), a leading Canadian research institution renowned for scientific innovation and technology transfer (Press release, Epitopea, SEP 26, 2024, View Source [SID1234646875]). Together, they will examine the feasibility of developing new immunotherapies to effectively treat patients with lung and ovarian cancers. This collaborative program was made possible by a grant of Canadian $1,499,457 from the government of Quebec.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CryptoMapTM is a platform resulting from the work of Professors Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer (IRIC) of UdeM. This platform has already allowed identification of non-mutated tumor antigens, uniquely expressed by cancer cells present in patients with the same type of cancer, called Cryptigens. During this project, novel CryptigenTM sets will be identified from patients with diverse origins enabling the creation of universal RNA-coding cancer vaccines targeting this new class of antigens. Epitopea will validate this unique approach to stimulate the immune system to precisely recognize and destroy cancer cells more rapidly and effectively.

This project has the potential to ‘unveil’ an unprecedented collection of CryptigensTM, an approach that distinguishes Epitopea from other cancer vaccine companies. Based on these data, Epitopea will be positioned to develop new RNA-based immunotherapies from this vast collection of patients samples and advance these innovative products into clinical trials. Epitopea’s mission aligns perfectly with Quebec’s initiatives to develop expertise in the field of RNA vaccines, as was highlighted in the recent AReNA announcement, Quebec’s new RNA cluster, which aims to position Quebec as a leader in RNA-based therapies(1).

"Our government is pleased to support CQDM’s initiative to facilitate research into new RNA-targeting therapies for the treatment of various forms of cancer. Québec is a global centre for innovation in the life sciences, and we remain committed to pushing forward on behalf of all Quebecers who are affected by cancer in one way or another,"

said Christine Fréchette, Minister of the Economy, Innovation and Energy, Minister responsible for Regional Economic Development and Minister responsible for the Greater Montreal Area.

"We are very pleased to partner with CQDM, UdeM, and our scientific co-founders, Drs. Perreault and Thibault to further extend the patient population that could potentially benefit from Epitopea’s transformative approach to treating cancer,"

commented Epitopea’s CEO, Alan C. Rigby.

"Epitopea will initially deploy these CryptigensTM in an off-the-shelf cancer vaccine approach, which we believe offers significant competitive advantages over personalized cancer vaccines being developed by many other organizations in the RNA immunotherapy ecosystem. Thanks to its refined versatility, we believe that the CryptoMapTM platform developed at UdeM could be applied to a wide range of tumor types, positively impacting patient responses in Quebec and across the globe."

"CQDM is proud to support a project that could transform the lives of cancer patients by providing accessible and effective RNA therapeutic solutions for difficult-to-treat diseases. This innovative collaboration between the Université de Montréal and Epitopea illustrates Quebec’s dynamism as a world leader in immunotherapy research. Not only will this project strengthen our understanding of cancer treatments, it will also position Quebec as a key player in the global vaccine and RNA therapy industry,"

On September 26, 2024 ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, reported that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference (Press release, ChromaDex, SEP 26, 2024, View Source [SID1234646874]). Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company Webcast

The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at View Source or on the Company’s website at chromadex.com. The webcast will also be available for replay following the event.

1×1 Meetings

Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×[email protected] or register for the event at View Sourceinvreg" target="_blank" title="View Sourceinvreg" rel="nofollow">View Source .

Further information on the conference is available at View Source .

For additional information on ChromaDex, visit www.chromadex.com.

On September 25, 2024 Allarta reported that its CEO Dr. Harald Stover will be presenting at the 2024 Cell and Gene Meeting on the Mesa (Press release, Allarta Life Science, SEP 25, 2024, View Source [SID1234647013]). He will be discussing Allarta’s hydrogel encapsulation to protect transplanted cells and highlighting Allarta’s work to enable a curative therapy for T1D as well as our transformative Cryogels to aid transport and storage.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation: October 7, 2024 @ 2:30pm MST
Location: Arizona Biltmore, Ballroom G

On September 25, 2024 ExThera Medical reported the completion of the Phase I OSCAR I STUDY (ONCObind CTC Removal Study NCT) at OU Health Stephenson Cancer Center, the clinical partner of the University of Oklahoma (Press release, ExThera Medical, SEP 25, 2024, View Source [SID1234646870]). The OSCAR study is a Prospective Single-Arm Feasibility Trial to evaluate the initial safety and signals of efficacy by determining the ability of the ONCObind Procedure Hemoperfusion Filter to remove Circulating Tumor Cells (CTCs) from the blood of patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A total of five patients with PDAC have completed the ONCObind Procedure with no safety concerns or signals that have been observed. Data has subsequently been submitted to the FDA for review and approval, in order to proceed to the second phase of the feasibility trial (OSCAR II), with a proposal for expanding the patient population to include Metastatic Colorectal Cancer (MCRC), in addition to metastatic PDAC.

"We are happy to report that the ONCObind Procedure was well tolerated by all patients," said ExThera Medical Chairman and President Bob Ward, Ph.D., NAE. "We were also pleased by the rapid reduction in patients’ sedimentation rates and their noticeable improvement in appetite."

Sanja Ilic, M.D., M.S., RAC and the chief regulatory officer for ExThera, added, "We have a great partnership with the team at Stephenson Cancer Center and look forward to partnering with them on future pancreatic cancer studies, with the potential to expand into colorectal cancer."

The ONCObind Procedure Hemoperfusion Filter is the product brand name for the Onco-Seraph platform technology, an extracorporeal blood filtration procedure designed to target and filter out CTCs from the bloodstream of patients. CTCs are shed from primary tumors and contribute to metastasis, which is responsible for most cancer-related deaths. The ONCObind Procedure uses a blood filter based on ExThera’s Seraph 100 Microbind Affinity Blood Filter technology, which has shown significant success in reducing CTCs in a recent in vitro study. Both the ONCObind Procedure Hemoperfusion Filter and the Seraph 100 Microbind Affinity Blood Filter are investigational medical devices in the United States and are not approved by the U.S. Food and Drug Administration for sale or distribution.

On September 25, 2024 Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, reported publication of the results of a phase II trial in resected pancreatic cancer (REACTIVE) in the Journal of Clinical Oncology (JCO) (Press release, Amphera, SEP 25, 2024, View Source [SID1234646869]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights from the REACTIVE trial in resected pancreatic cancer:

The phase II trial, including 38 patients with resected pancreatic cancer who had completed standard-of-care chemotherapy, met the primary endpoint demonstrating a clinically significant increase in 2-year recurrence-free survival of 64% compared to an expected 40%. This was accompanied with only low grade side effects.
The 2-year overall survival rate was 83%. Translational immune-profiling supports an induction of an effective immune-activation against the tumor.
Patients in the REACTIVE trial received 3 bi-weekly injections of Amphera’s MesoPher dendritic cell therapy and booster injections at 4 and 7 months.
Prof Casper van Eijck, pancreatic cancer surgeon, Erasmus MC in Rotterdam and Principal Investigator of the REACTIVE trial said: "These results are promising as recurrence rates are high and long-term survival is rare in this patient group. We are now preparing a randomized phase II/III trial to replicate this efficacy signal. I am happy to announce that the DPCG, the Dutch Pancreatic Cancer Group, one of the world’s leading research groups in this field, has committed to participate in this trial."

Ilona Enninga, COO of Amphera added "We have created a promising cell therapy bridgehead. MesoPher is derisked as to safety and manufacturing. This trial shows that MesoPher induces a clinically meaningful immune response, causing an increase in patient survival. EMA has granted MesoPher Orphan Designation for pancreatic cancer, based on potential significant benefit. We are very happy to announce today that the FDA has granted MesoPher Orphan Designation for pancreatic cancer as well."

Rob Meijer, CEO of Amphera said "The potential of MesoPher cell therapy is increasingly recognized in the scientific and regulatory community. The JCO publication will certainly help us to realize the necessary funding and partners for our next step: a randomized trial in resected pancreatic cancer."